Gilead Sciences (GILD) Cash from Financing Activities (2016 - 2025)
Historic Cash from Financing Activities for Gilead Sciences (GILD) over the last 17 years, with Q3 2025 value amounting to -$1.5 billion.
- Gilead Sciences' Cash from Financing Activities fell 797.68% to -$1.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 billion, marking a year-over-year increase of 3783.86%. This contributed to the annual value of -$3.4 billion for FY2024, which is 3301.46% up from last year.
- Gilead Sciences' Cash from Financing Activities amounted to -$1.5 billion in Q3 2025, which was down 797.68% from -$1.6 billion recorded in Q2 2025.
- Over the past 5 years, Gilead Sciences' Cash from Financing Activities peaked at $2.3 billion during Q4 2024, and registered a low of -$3.5 billion during Q3 2021.
- Its 5-year average for Cash from Financing Activities is -$1.6 billion, with a median of -$1.5 billion in 2023.
- In the last 5 years, Gilead Sciences' Cash from Financing Activities plummeted by 158244.27% in 2021 and then soared by 30564.15% in 2024.
- Over the past 5 years, Gilead Sciences' Cash from Financing Activities (Quarter) stood at -$1.9 billion in 2021, then grew by 19.98% to -$1.6 billion in 2022, then grew by 29.28% to -$1.1 billion in 2023, then skyrocketed by 305.64% to $2.3 billion in 2024, then tumbled by 165.88% to -$1.5 billion in 2025.
- Its Cash from Financing Activities stands at -$1.5 billion for Q3 2025, versus -$1.6 billion for Q2 2025 and -$3.4 billion for Q1 2025.